Prion fingerprints detected with glowing molecule
An effective and sensitive new method for detecting and characterizing prions, the infectious compounds behind diseases like mad cow disease, is now being launched by researchers at Linköping University in Sweden, among other institutions. The method now being presented in the journal Nature Methods is based on a fluorescent molecule, a so-called conjugated polymer, which was developed at Linköping University.
The research team infected genetically identical laboratory mice with BSE, scrapie (which afflicts sheep), and CWD (chronic wasting disease or "mad elk disease," which is epidemic in the central U.S.) for several generations in a row. Gradually new strains of prions emerge, making the diseases more fatal to the mice. Tissue samples from mice were examined using the fluorescent molecule, which seeks out and binds with prions. This is signaled by a shift in color. By tweaking the molecule, the team has been able to get it to show different colors depending on the structure of the prioneach prion strain emits its own optical fingerprint.
This is an important difference compared with other techniques used to find prions, such as antibodies and the well-known stain Congo red. The technique has also proven to work well on tissue sections from dead animals, such as cows infected with BSE. Now the scientists want to move on and look for alternative sample-taking methods for diagnosing and tracking prion diseases in humans in early stages.
The method would then be useful for screening blood products, since there is a risk that people can be carriers of prions without having any symptoms of disease. In the U.K. it was discovered that 66 people had received blood from blood donors who were infected with the human form of BSE (a variant of Creutzfeldt-Jakob's disease, vCJD), and among them, four individuals have been shown to be infected.
"Using our methods, we can directly see the structure of the prions and thereby deduce the disease," says Peter Nilsson, one of the lead authors of the article. Nilsson developed the technique as a doctoral student at Linköping University and now, as a post-doctoral fellow with Professor Adrian Aguzzi's research team in Zürich, has been applying the technology to prion diseases. After New Year's he will assume a post-doc position at Linköping.
Original publication: Christina J Sigurdson, K Peter R Nilsson, Simone Hornemann, Guiseppe Manco, Magdalini Polymenidou, Petra Schwartz, Mario Leclerc, Per Hammarström, Kurt Wüthrich, and Adriano Aguzzi; "Prion strain discrimination using luminescent conjugated polymers"; Nature Methods 2007.
Most read news
Organizations
Other news from the department science
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
SERS increases in creases
Scientists develop “scifi-RNA-seq” method for ultra-high-throughput RNA sequencing in single cells - An efficient high-throughput method with a wide range of applications
Faster and more efficient thanks to "defects" - Three-dimensional photonic crystals will revolutionize telecommunications
LDL particle measurement by NMR recognized by ADA, ACC - Consensus panel assesses lipoprotein management
Xantos Biomedicine and QIAGEN AnnounceCo-Marketing Agreement for RNAi Library with High-Content Cellular Screening System
University of Toronto chemists uncover green catalysts